Microdose GLP-1: dosing math, evidence, and how to start safely in 2026.

Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed May 19, 2026.

What is microdose GLP-1?

Microdosing a GLP-1 means using semaglutide or tirzepatide at a dose that sits below the FDA-approved starting titration. The starting dose on the Wegovy label is 0.25 mg of semaglutide once weekly, titrated to a 2.4 mg maintenance dose. The starting dose on the Zepbound label is 2.5 mg of tirzepatide once weekly, titrated to a 15 mg maintenance dose. A microdose is any clinically supervised dose below that starter rung, typically 0.10 to 0.20 mg per week for semaglutide and 0.5 to 2.0 mg per week for tirzepatide.

The molecule does not change. The receptor pharmacology does not change. The weekly injection cadence does not change. Only the amount per dose is smaller. Patients choose microdose protocols to minimize nausea and other GI side effects, to lower medication cost, to maintain weight loss after a standard-dose protocol, or to target modest weight loss for a lower starting BMI than the standard-dose trials enrolled.

How microdose GLP-1 works

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Both molecules suppress appetite by binding receptors in the hypothalamus, slow gastric emptying, and improve insulin sensitivity. The receptor-binding curve is continuous, not all-or-nothing. A microdose produces partial receptor occupancy, which translates to a partial clinical effect: some appetite suppression, some delay in gastric emptying, some improvement in glycemic control. The weekly subcutaneous dosing interval is preserved because the half-life of both molecules (about a week) is what determines cadence, not the dose magnitude.

This is the pharmacological argument for why a microdose can do useful clinical work at all. The dose-response curve flattens at higher exposures but does not start flat. A dose that produces, for example, 40 percent receptor occupancy will not give a patient the same weight loss as a dose that produces 90 percent occupancy, but it will not give zero effect either.

How to microdose GLP-1 (5 steps)

The procedure below is the same one your RxPepsDirect prescriber will document on your protocol sheet. The detailed injection technique (site selection, needle angle, after-care) lives in our full subcutaneous injection guide. The steps here cover the protocol layer above the injection itself.

1. Work with a licensed prescriber. Complete an intake with a state-licensed nurse practitioner or physician. Disclose any history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, gastroparesis, pregnancy, or insulin use. The prescriber confirms candidacy, orders baseline labs where indicated, and writes a patient-specific prescription for a microdose protocol.
2. Choose the lowest available titration concentration. Microdosing is easier and more accurate when you draw a small number of units from a low-concentration vial than when you try to measure a tiny volume from a high-concentration vial. RxPepsDirect dispenses semaglutide at 0.6 mg/mL (the $25 starter vial) and tirzepatide at 6 mg/mL (the $45 starter vial). These concentrations are designed to support both standard titration and microdose protocols.
3. Inject your microdose once weekly. Pick a consistent day and time. Sanitize the rubber stopper, draw the prescribed number of units on a U-100 insulin syringe, and inject subcutaneously into the abdomen, upper outer thigh, or back of the upper arm. Rotate sites week to week to avoid lipohypertrophy.
4. Hold the microdose for 8 to 12 weeks before adjusting. GLP-1 effects on appetite and weight build over 6 to 12 weeks at steady state. Do not titrate up or down inside that window unless you are experiencing intolerable side effects or hypoglycemia. A premature titration prevents you and your prescriber from knowing what the current dose can actually deliver.
5. Track and review with your prescriber. Log weekly weight, weekly appetite rating, any side effects, and any deviations from the schedule. At week 12, review the trend with your prescriber. Decisions to maintain, increase, or stop the microdose protocol are based on measured response, tolerance, and updated labs where indicated.

Microdose dosing math (semaglutide and tirzepatide)

The math below uses the two RxPepsDirect starter vials and a standard U-100 insulin syringe (100 units per mL). All vial-life calculations are bounded by Optimal Balance Pharmacy's published beyond-use date (BUD) of up to 120 days from compounding.

Semaglutide microdose ($25 starter vial: 1.2 mg total, 0.6 mg/mL, 2 mL)

• 0.10 mg per week = 17 units per injection. Vial lasts about 12 weeks. Medication cost roughly $2.08 per week.
• 0.15 mg per week = 25 units per injection. Vial lasts about 8 weeks. Medication cost roughly $3.13 per week.
• 0.20 mg per week = 33 units per injection. Vial lasts about 6 weeks. Medication cost roughly $4.17 per week.
• For reference: the FDA-approved Wegovy starter dose of 0.25 mg per week = 42 units per injection. Vial lasts about 5 weeks at roughly $5.20 per week.

Tirzepatide microdose ($45 starter vial: 12 mg total, 6 mg/mL, 2 mL)

• 0.5 mg per week = 8 units per injection. Vial is BUD-capped at about 17 weeks of use, working out to roughly $2.65 per week.
• 1.0 mg per week = 17 units per injection. Vial lasts about 12 weeks. Medication cost roughly $3.75 per week.
• 1.5 mg per week = 25 units per injection. Vial lasts about 8 weeks. Medication cost roughly $5.63 per week.
• 2.0 mg per week = 33 units per injection. Vial lasts about 6 weeks. Medication cost roughly $7.50 per week.
• For reference: the FDA-approved Zepbound starter dose of 2.5 mg per week = 42 units per injection. Vial lasts about 5 weeks at roughly $9.38 per week.

Add a one-time $39 visit fee per medical review. There is no subscription, no monthly auto-charge, and no auto-refill on any RxPepsDirect prescription. You re-order vials individually when your current vial is approaching its BUD or running low.

What the evidence actually says

The microdose framing for GLP-1 therapy entered the formal medical literature in 2025. Komé and colleagues at the University of North Carolina (with John Buse, a senior diabetes investigator, as co-author) published a letter in Diabetes Care describing microdose semaglutide as fractional dosing below the standard protocol, titrated to each patient's individual tolerance and response (Komé et al. 2025). A follow-on comment by Tejera-Pérez in the same journal expanded the proposed clinical use cases to include medication transitions, drug-shortage workarounds, post-surgical reintroduction, and adjunctive support for very-low-calorie diets, while stating explicitly that microdosing “is not currently included in clinical guidelines, and no randomized controlled trials support microdosing” (Tejera-Pérez 2025).

The strongest quantitative argument for sub-standard dosing comes from a 2025 pharmacokinetic and pharmacodynamic modeling study by Cengiz, Wu, and Lawley in Diabetes, Obesity and Metabolism. The authors simulated alternative dosing regimens of semaglutide and tirzepatide and reported that switching from once-weekly to once-every-two-weeks dosing maintained roughly 69 to 82 percent of weight loss while halving cost. The paper does not study subtherapeutic per-dose microdosing directly, but its mechanistic conclusion (lower total exposure preserves a substantial share of the weight-loss benefit) is the foundation of the microdose rationale (Cengiz, Wu, Lawley 2025).

The critic's case was put plainly by Reshma Ramachandran, a Yale health-services researcher, in a November 2025 STAT News investigation: patients on intentional microdose protocols are “guinea pigs, both on the efficacy side and the safety side.” The honest position is that randomized comparative trials of microdose versus standard dose have not been done, that the modeling and mechanistic case is reasonable but unproven, and that microdose protocols belong to a narrow set of clinical situations rather than being the default starting point for every patient.

What we expect microdosing to deliver, based on mechanism and modeling: slower and smaller weight loss than standard dosing, lower side-effect burden, possibly better preservation of lean mass (this has not been directly measured in microdose protocols), and lower cost.

Microdose vs standard dose: tradeoffs

Microdose protocols are not a free lunch. Every advantage on the tolerability and cost sides comes with a corresponding cost on the magnitude and pace of the clinical effect.

• Weight loss magnitude. Standard-dose semaglutide and tirzepatide trials reported 15 to 22 percent body-weight reduction over 68 to 72 weeks. Microdose protocols realistically deliver 3 to 8 percent over a comparable window. The right comparison is to your weight-loss goal, not to the headline numbers from the Phase III trials.
• Side effects. The dose-limiting GI side effects of GLP-1 therapy scale with systemic exposure. Microdosing generally keeps patients well below the threshold at which problematic nausea, vomiting, and constipation occur.
• Cost. Microdosing extends each starter vial substantially. A $25 semaglutide vial that lasts 5 weeks at the FDA starter dose lasts 12 weeks at 0.10 mg per week, dropping medication cost from about $5.20 to about $2.08 per week.
• Time to results. Microdose protocols build slowly. Most patients will not see meaningful weight change in the first 4 to 6 weeks. Standard dosing also has a slow on-ramp, but the eventual ceiling is much higher.
• Muscle preservation. Some clinicians hypothesize that microdosing reduces the lean-mass loss seen at standard doses, on the theory that smaller appetite suppression translates to better protein intake. The hypothesis is plausible and not yet directly tested.

Who is a good candidate for microdose GLP-1?

Microdose protocols are most defensible for patients who fit one or more of the following profiles. They are not a default starting point for every patient seeking GLP-1 therapy, and they are not intended to replace standard-dose titration for patients who would be better served by it.

• Lower BMI seeking modest loss. Patients with a starting BMI in the 25 to 29 range who want to lose 5 to 10 pounds with appetite regulation rather than aggressive titration.
• Side-effect sensitive. Patients who experienced intolerable nausea, vomiting, or fatigue on a standard-dose protocol and would otherwise discontinue therapy entirely.
• Maintenance after standard-dose weight loss. Patients who reached their weight-loss goal at maintenance dosing and want to step down to the lowest dose that prevents regain.
• Cost-sensitive. Patients who cannot sustain standard-dose monthly spend and would otherwise stop therapy. Microdosing at $2.08 to $4.17 per week with a 503A pharmacy is the most affordable supervised GLP-1 protocol in the U.S. market.
• Adjunctive support. Patients on a structured ketogenic or very-low-calorie diet who want mild appetite regulation without the dose intensity of standard protocols.

Microdose protocols are generally not indicated for patients with a BMI above 35 seeking substantial weight loss, patients with type 2 diabetes requiring glycemic control to a specific A1C target, or patients who have already failed standard-dose protocols on efficacy (not tolerability) grounds. The contraindications that apply to GLP-1 therapy at any dose apply equally to microdose protocols: medullary thyroid carcinoma history, MEN2 syndrome, active pancreatitis, severe gastroparesis, and pregnancy.

How RxPepsDirect prescribes microdose protocols

RxPepsDirect prices semaglutide and tirzepatide per milligram with no subscription. Per-mg pricing is the structural reason microdose protocols are dramatically cheaper through RxPepsDirect than through competitors that bundle a fixed monthly subscription on top of a fixed monthly dose. When you take less per week, your $25 semaglutide vial or $45 tirzepatide vial covers more weeks.

Every prescription is reviewed and signed by a state-licensed nurse practitioner or physician on the RxPepsDirect medical team, including the intake review that confirms candidacy for a microdose protocol specifically. Prescriptions are dispensed by Optimal Balance Pharmacy in Texas, ship pre-reconstituted via FedEx overnight in a reusable cooled travel case, and arrive ready to inject. Sterile U-100 insulin syringes are included with every shipment. The medication carries a BUD of up to 120 days from compounding, which fully covers even the lowest-dose protocols.

There is no auto-refill on any GLP-1 prescription. You re-order vials individually when your current vial is nearing its BUD or is running low, which gives you and your prescriber a deliberate checkpoint at each refill rather than a passive monthly subscription. The $39 visit fee is one-time per medical review, not recurring.

For broader context on the two molecules side by side, see our comparison guide at semaglutide vs tirzepatide for weight loss. For the carrier-choice decision (B-12 versus glycine), see glycine vs B12 carrier. For the underlying legal framework that makes 503A patient-specific compounding possible, see are peptides legal in the United States.

Bottom line

Microdosing GLP-1 means running semaglutide or tirzepatide below the FDA-approved starting dose to capture appetite regulation and metabolic benefits at lower side-effect burden and lower cost. The published clinical evidence is small and growing; randomized comparative trials have not been done. The pharmacology supports partial-occupancy effects, and the modeling literature supports lower-exposure regimens preserving most of the weight-loss benefit. The protocol is most defensible for lower-BMI patients seeking modest loss, side-effect-sensitive patients, post-standard-dose maintenance, and cost-sensitive patients. The RxPepsDirect $25 semaglutide starter vial and $45 tirzepatide starter vial, both at their lowest titration concentration, are designed to support both standard and microdose protocols. A medical review with a state-licensed prescriber is required to start; the visit fee is $39, one time.

Start a $39 visit→